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a b s t r a c t
Introduction: Liver transplantation is currently the only curative therapy for end-stage liver failure;
however, establishment of alternative treatments is required owing to the serious donor organ shortage.
Here, we propose a novel model of hybrid three-dimensional artificial livers using both human induced
pluripotent stem cells (hiPSCs) and a rat decellularized liver serving as a scaffold.
Methods: Rat liver harvesting and decellularization were performed as reported in our previous studies.
The decellularized liver scaffold was recellularized with hiPSC-derived hepatocyte-like cells (hiPSC-HLCs)
through the biliary duct. The recellularized liver graft was continuously perfused with the culture
medium using a pump at a flow rate of 0.5 mL/min in a standard CO2 (5%) cell incubator at 37 C.
Results: After 48 h of continuous perfusion culture, the hiPSC-HLCs of the recellularized liver distributed
into the parenchymal space. Furthermore, the recellularized liver expressed the albumin (ALB) and
CYP3A4 genes, and secreted human ALB into the culture medium.
Conclusion: Novel hybrid artificial livers using hiPSCs and rat decellularized liver scaffolds were
successfully generated, which possessed human hepatic functions.
© 2019, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
1. Introduction
Liver transplantation is the only curative treatment for end-
stage liver failure. However, the serious donor organ shortage
presents a global problem. Although the need for alternative op-
tions for liver replacement, including bioartificial livers, is well
recognized, the development of a transplantable artificial whole
liver has not yet been realized, mainly owing to the difficulty of
reproducing a complicated three-dimensional (3D) structure of
native livers. Human induced pluripotent stem cells (hiPSCs) and
human iPSC-derived hepatocyte-like cells (hiPSC-HLCs) are
considered promising as suitable cell sources for alternative
treatments of liver failure. However, the difficulty in constructing a
transplantable 3D liver using hiPSCs or hiPSC-HLCs remains
unsolved.
The recent development of a decellularization technique has
now made it possible to construct an acellular 3D organ scaffold,
including the heart [1], lung [2], liver [3, 4], and kidney [5]. A
decellularized liver scaffold, which consists of an extracellular
matrix (ECM) retaining the tissue-specific 3D ultrastructure, intact
vascular networks for nutrient and gas transport, and molecules
that may promote cell attachment and organ-specific differentia-
tion of progenitor cells, is highly anticipated as a promising new
material for whole-liver engineering by repopulating suitable
hepatic cells, namely recellularization [6]. We have constructed an
artificial recellularized liver with rat adult primary hepatocytes or
mouse fetal primary hepatocytes, and evaluated their liver function
[6, 7]. However, to our best knowledge, a recellularized artificial
liver using hiPSCs has not yet been reported.
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Thus, the aim of this study was to develop a novel artificial liver
model using hiPSCs and rat decellularized liver scaffolds, and to
evaluate its liver function.
2. Methods
2.1. Liver harvest and decellularization
Male Lewis rats (250e300 g; SLC, Hamamatsu, Japan) were used
for liver harvesting and preparation of the decellularized liver
scaffolds. All animal experimental protocols were approved by the
Kyoto University Animal Experimentation Committee, and were
performed in accordance with the Animal Protection Guidelines of
Kyoto University.
Rat liver harvesting and decellularization were performed as
reported in our previous studies [6e8]. The harvested livers were
cannulated with a 24-gauge cannula in the biliary duct (BD) and a
20-gauge cannula in the portal vein (PV), and were stored in cell
culture dishes with phosphate-buffered saline (PBS). The decellu-
larization protocol is schematically summarized in Fig. 1. In brief,
the livers were frozen at 80 C and thawed at room temperature,
followed by perfusion with 0.02% trypsin/0.05% EGTA solution
through the PV for 1 h at 37 C to detach cells from the ECM.
Subsequently, a 1% Triton X-100/0.05% EGTA solution was perfused
at 1 mL/min for 18e24 h until the livers were decellularized. The
decellularized liverswere then perfusedwith 0.1% peracetic acid for
2 h for sterilization, followed by perfusion with PBS.
2.2. hiPSCs culture
The experiments using hiPSCs were approved by the Ethics
Committee of Kyoto University, and informed consent was obtained
from the donors of hiPSCs.
The hiPSC cell line, 585A1 (Kyoto University, Japan), was main-
tained on feeder layers of mitomycin C-treated STO/Neo resistant/
LIF (SNL) feeder cells in Primate ES medium (ReproCELL, Tokyo,
Japan) with 4 ng/mL recombinant human basic fibroblast growth
factor (Wako, Osaka, Japan) and 500 U/mL penicillin/streptomycin
(PS; Thermo Fisher Scientific, Waltham, MA, USA). For routine
passaging, hiPSC colonies were treated with dissociation solution
consisting of 0.25% trypsin (Thermo Fisher Scientific), 0.1% colla-
genase IV (Thermo Fisher Scientific), 20% knockout serum
replacement (KSR; Thermo Fisher Scientific), and 1 mM CaCl2 in
PBS (CTK dissociation solution), and split at a ratio between 1:8
and 1:12.
2.3. Differentiation of hiPSCs into hiPSC-HLCs
Differentiation protocols of hiPSCs into hiPSC-HLCs (Fig. 2) were
based on our previous reports [9e11]. In brief, hiPSC colonies were
treated with CTK dissociation solution. The cells were dissociated to
single cells by mild pipetting after treatment with Accutase (Inno-
vative Cell Technologies, San Diego, CA, USA) for 10e20 min and
seeded on Matrigel-coated plates (Corning Incorporated, Corning,
NY, USA) at a density of 1.0 105 cells/cm2 with the stage 1 medium
consisting of RPMI1640 (Nacalai Tesque, Kyoto, Japan) supplemented
with 1  B27 (Thermo Fisher Scientific), 500 U/mL PS, 100 ng/mL
recombinant human/mouse/rat activin A (R&D Systems, Minneap-
olis, MN, USA), and 1 mM CHIR99021 (Axon Medchem, Groningen,
the Netherlands). For the first day of differentiation culture, the
ROCK inhibitor Y27632 (10 mM;Wako) was added to the medium to
support cell survival, and then the cells were cultured for a total of
5e6 days. For stage 2, the cells were cultured in the stage 2 medium
consisting of Knockout-Dulbecco's modified Eagle medium (Thermo
Fisher Scientific), 20% KSR, 1 mM L-glutamine, 1% nonessential
amino acids, 0.1 mM 2-mercaptoethanol, and 1% dimethyl sulfoxide
(Sigma-Aldrich, St. Louis, MO, USA) for 6 days. For stage 3, the cells
were cultured in the stage 3 medium consisting of hepatocyte cul-
ture medium (Lonza, Basel, Switzerland) supplemented with 20 ng/
mL recombinant humanhepatocyte growth factor (Peprotech, Rocky
Hill, NJ, USA) and 20 ng/mL recombinant human oncostatin M
(Peprotech) for 7e8 days.
2.4. Isolation of hiPSC-HLCs and recellularization of the
decellularized liver scaffolds
The hiPSC-HLCs on stage 3, day 8 were dissociated by mild
pipetting after treatment with Accumax (Innovative Cell Technol-
ogies) for 30 min at 37 C, and the decellularized liver scaffolds
were recellularized through the BD as we previously reported
[6e8]. In brief, a decellularized liver scaffold was placed in a 100-
mm culture dish and perfused with 20 mL of the stage 3 medium
through the PV prior to recellularization. A total of 1.6  107 hiPSC-
HLCs resuspended in 20mL of the culture mediumwere introduced
into the liver scaffold through the BD at a flow rate of 1 mL/min.
2.5. Perfusion culture of the recellularized liver grafts
Perfusion culture of the recellularized liver grafts was per-
formed as we previously reported [6, 7]. In brief, after 3 h of static
culture, the recellularized liver graft was transferred to a custom-
ized chamber for perfusion culture. The recellularized liver graft
was connected to a recirculation circuit by a cannula inserted into
the PV and continuously perfused with the stage 3 medium, using a
Perista pump (ATTO, Tokyo, Japan) at a flow rate of 0.5 mL/min to
prevent shear stress and mechanical damage to the engrafted cells
(Fig. 3). The entire perfusion system was placed in a standard CO2
(5%) cell incubator at 37 C. As a control, perfusion culture of the
decellularized liver graft without recellularization was also
performed by using the same method.
2.6. Immunocytochemistry of hiPSC-HLCs
Immunocytochemistry of hiPSC-HLCs was performed as previ-
ously reported [12, 13]. Samples were incubated overnight at 4 C
with primary antibodies against SOX17 (1:100; R & D Systems,
AF1924), HNF4a (1:50; Santa Cruz Biotechnology, Dallas, TX, USA,
sc-374229), albumin (ALB; 1:500; Bethyl, Montgomery, TX, USA,
A80-229A), alpha-fetoprotein (AFP; 1:500; Sigma-Aldrich A8452),
and CYP3A4 (1:100; Proteintech, Rosemont, IL, USA, 18227-1-AP).
After washing, the stained samples were incubated with Alexa 488-
conjugated donkey anti-goat IgG (1:500; Thermo Fisher Scientific)
Fig. 1. Decellularization protocol of a rat whole liver.
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for SOX17 or ALB, Alexa 488-conjugated donkey anti-rabbit IgG
(1:200; Thermo Fisher Scientific) for CYP3A4, or Alexa 555-
conjugated goat anti-mouse IgG (1:500; Thermo Fisher Scientific)
for HNF4a or AFP detection. After washing, the samples were
covered with Vectashield mounting medium containing 4,6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlin-
game, CA, USA). All samples were imaged using a BZ-9000
fluorescence microscope (Keyence, Osaka, Japan).
2.7. Histology and immunohistochemistry of decellularized liver
scaffolds and recellularized liver grafts
Decellularized liver scaffolds and recellularized liver grafts were
fixed with 4% paraformaldehyde, embedded in paraffin, and cut
into 4-mm-thick sections. Hematoxylin and eosin (H&E) staining
was performed according to standard protocols.
Immunofluorescent analyses were performed as reported pre-
viously [6, 7]. Antigen retrieval was achievedwith a Target Retrieval
Solution (Dako, Glostrup, Denmark). Non-specific binding was
blocked with 1.4% bovine serum albumin (Sigma-Aldrich) dissolved
in 0.1% saponin (Wako) in PBS. Sections were incubated overnight
at 4 C with primary antibodies of ALB, AFP, and CYP3A4. After
washing, the stained sections were incubated with Alexa 488-
conjugated donkey anti-goat IgG (1:500) for ALB, Alexa 488-
conjugated donkey anti-rabbit IgG (1:200) for CYP3A4, or Alexa
555-conjugated goat anti-mouse IgG (1:500) for AFP detection for
2 h at room temperature. After washing, the stained sections were
covered with Vectashield mounting medium containing DAPI. All
samples were imaged using a BZ-9000 fluorescence microscope
(Keyence).
2.8. Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from the recellularized hiPSC-HLCs
after 48 h of perfusion culture using a Pure Link RNA Mini Kit
(Invitrogen), and 200 ng of total RNA was reverse-transcribed to
cDNA using ReverTra Ace (TOYOBO, Osaka, Japan) according to
the manufacturer protocols. The following primers were amplified:
HNF4a forward 50eCCAAGTACATCCCAGCTTTC, reverse 50-
TTGGCATCTGGGTCAAAG; ALB forward 50-TGGGCAGCAAATGTTG-
TAAA, reverse 50-CTCCTTATCGTCAGCCTTGC; and CYP3A4 forward
50eCCTTACACATACACACCCTTTGGAAGT, reverse 50-AGCTCAATG-
CATGTACAGAATCCCCGGTTA. RT-PCR was performed as previously
described [13e15]. RT-PCR was also performed for hiPSCs and
hiPSC-HLCs at stage 3, day 8 in the same manner.
2.9. Evaluation of recellularized liver function
The culture medium of the recellularized liver graft and
decellularized liver graft was collected after 48 h of perfusion,
and the human ALB content was measured using the human
albumin enzyme-linked immunosorbent assay quantitation kit
(Bethyl) according to the manufacturer's protocol. The human
ALB content in the medium of undifferentiated hiPSCs and hiPSC-
HLCs at stage 3, day 8 in vitro was also measured by using the
same method.
2.10. Statistical analysis
Data are expressed as mean ± standard error of mean. Statistical
analysis was performed using GraphPad Prism for Windows,
version 6.0 (GraphPad Software, La Jolla, CA, USA). Statistical sig-
nificance was defined as p < 0.05. The cumulative human albumin
production of each groupwas compared using Student's t-test with
Bonferroni correction.
3. Results
3.1. Decellularization of the whole liver
A translucent acellular liver scaffold was obtained after 24 h of
the decellularization procedure (Fig. 4A). Histological analysis of
the decellularized liver scaffold confirmed the lack of nuclei or
cytoplasmic components in the scaffolds (Fig. 4A). Crystal violet
Fig. 2. Differentiation protocols of hiPSCs into hiPSC-HLCs.
Fig. 3. The recellularized liver graft (RL) was connected to the recirculation circuit by a
cannula inserted into the PV, and continuously perfused with the culture medium
using a Perista pump. (A) Pump continuously perfusing the culture medium. (B) Inflow
into RL. (C) Connection port into the PV cannula of RL. (D) RL. (E) Culture medium. (F)
Aspiration port of the culture medium in the culture dish. (G) Outflow from the
culture dish.
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staining further showed that the PV and BD were intact after the
decellularization (Fig. 4B), allowing for recellularization and
perfusion culture.
3.2. Immunocytochemical evaluation of hiPSC-HLCs
Immunofluorescent staining showed that the hiPSC-HLCs
expressed liver-related markers, including SOX17 at stage 1, day 6
(Fig. 5A), HNF4a and AFP at stage 2, day 6 (Fig. 5B), and ALB, AFP,
and CYP3A4 at stage 3, day 8 (Fig. 5C). These findings confirmed
that the hiPSC-HLCs showed hepatocyte-like characteristics.
3.3. Macroscopic and histological observations of the liver
recellularized with hiPSC-HLCs
Macroscopic observation of the recellularized liver showed that
hiPSC-HLC clusters were broadly distributed in the liver lobe
(Fig. 6A). H&E staining of the recellularized liver after 48 h of
perfusion culture demonstrated that the vascular structures were
intact, and the hiPSC-HLCs were distributed into the parenchymal
space (Fig. 6B). The cell array was similar to that of epithelial cells,
and the cell structure, including nuclei or cytoplasm, was retained
(Fig. 6C and D).
Fig. 4. Preparation of the rat decellularized whole liver scaffold and evaluation of the seeding or perfusion route. (A) Macroscopic and histological comparison of rat native (left
panels) and decellularized livers (right panels). H&E staining showed no remaining nuclei or cytoplasmic components in the scaffolds (lower right panel). Scale bars: 100 mm. (B)
Crystal violet staining of the intrahepatic portal vein (PV; upper panel) and biliary duct (BD; lower panel) demonstrated their patency.
Fig. 5. Immunostaining analysis demonstrated hepatic differentiation of hiPSCs into hiPSC-HLCs in vitro. (A) SOX17 (green) expression at stage 1, day 6. (B) HNF4a (red) and AFP
(red) expression at stage 2, day 6. (C) Albumin (ALB; green), AFP (red), and CYP3A4 (green) expression at stage 3, day 8. Scale bars: 100 mm. In all figures, blue fluorescence indicates
DAPI.
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3.4. Evaluation of hepatic function of the recellularized liver graft
Immunofluorescent staining of the recellularized liver after 48 h
of perfusion culture showed that hiPSC-HLCs seeded through the
BD expressed liver-related markers, including ALB, AFP, and
CYP3A4 (Fig. 7A). RT-PCR analysis demonstrated the mRNA
expression of HNF4a, ALB, and CYP3A4 in the hiPSC-HLCs following
48 h of perfusion culture in the recellularized liver. The mRNA
expression level of CYP3A4 in the recellularized liver after 48 h of
perfusion culture appeared to be higher than that in the hiPSC-
HLCs at stage 3, day 8 in vitro (Fig. 7B). The cumulative human
ALB secretion in the recellularized livers after 48 h of perfusion
culture was 31.34 ± 16.82 ng/106 cells, whereas the cumulative
human ALB secretion of hiPSC-HLCs at stage3, day8 in vitro for 48 h
was 172.0 ± 12.03 ng/106 cells (p < 0.05). The cumulative human
ALB secretion in the decellularized liver after 48 h of perfusion
culture and undifferentiated hiPSCs was undetectable (Fig. 7C).
4. Discussion
In this study, we successfully developed a novel artificial liver
model using hiPSCs and a rat decellularized liver scaffold, and
demonstrated its potential for human liver function. RT-PCR and
immunofluorescence analysis showed the expression of human ALB
and CYP3A4 in the recellularized liver. Moreover, ELISA revealed that
the recellularized liver secreted human ALB. These results suggest
that the 3D artificial livers generated in this study have human liver-
characteristic function, including the secretion of liver-related
proteins or drug metabolism. Functional recellularized livers with
non-human iPSCs have been reported previously [16]; however, to
our best knowledge, this is thefirst study to generate a recellularized
liver model with human hepatic function using hiPSCs.
On the other hand, the fact that AFP was still expressed in the
recellularized liver suggested that the hiPSC-HLCs in the recellu-
larized liver after perfusion culture were not sufficiently mature.
The ALB secretion ability of the recellularized livers was approxi-
mately 1/5 to 1/6 that of hiPSC-HLCs in vitro, and 1/70 to 1/100 that
of the liver recellularized with adult rat primary hepatocytes [6, 7].
We speculated that this was because the procedure of isolating
hiPSC-HLCs before recellularization might cause cell damage and
decrease hepatocyte function. Moreover, bile production in the
recellularized liver was not confirmed. These deficiencies could
result in unsatisfactory hepatic functions of the recellularized liver
graft with hiPSC-HLCs, which is a limitation of the current method
that should be overcome with optimization of the protocol in
further studies.
Xenogeneic decellularized scaffolds have been reported to show
low immunogenicity [17]; thus, decellularized liver scaffolds derived
from other species could be suitable for human organ trans-
plantation without the risk of severe immune rejection. Further-
more, the decellularized scaffold retained its intact vascular
structure. Thus, the decellularized organs can be transplanted in vivo
by vascular anastomosis as well as through current transplant sur-
gical methods. This is the main advantage of artificial liver engi-
neering using a decellularized scaffold in comparisonwithmicro-3D
liver buds derived from hiPSCs [18, 19]. We previously reported that
Fig. 6. Macroscopic and H&E staining observation of the liver graft recellularized with hiPSC-HLCs after 48 h of perfusion culture. Macroscopic observation of the recellularized liver
showed that hiPSC-HLC clusters widely spread in the liver lobe (A). The cells were distributed into the parenchymal space, and the portal vein (PV) and hepatic vein (HV) were intact
(B). The cell array was similar to that of epithelial cells, and the cell structures, including nuclei or cytoplasm, were retained (C, D). Scale bars: 100 mm.
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rat primary hepatocytes could be more efficiently distributed into
the parenchymal space of the decellularized liver through the BD,
rather than through the PV [6]. Thus, in the present study, the hiPSC-
HLCswere injected into the decellularized liver scaffolds through the
BD, and the hiPSC-HLCs were distributed and engrafted in the
parenchymal space of the rat decellularized livers. This result sug-
gested that the BD was an appropriate recellularization pathway
regardless of the hepatocyte type. For transplantable liver engi-
neering in the future, recellularization through the BDmight be very
advantageous because the PV remains intact; moreover, re-
endothelialization of the PV could be performed to prevent throm-
bogenesis, which would also maintain the blood perfusion of arti-
ficial livers. We have previously reported that re-endothelialization
using rat primary liver sinusoidal endothelial cells maintained the
hepatic function of the recellularized liver with rat primary hepa-
tocytes, and supported hepatocyte viability under blood perfusion in
the recellularized liver graft owing to their antithrombogenicity [7].
Re-endothelialization using human-derived endothelial cells and
co-culture with hiPSC-HLCs still presents several challenges, which
should be addressed in future studies.
5. Conclusion
We successfully developed a novel artificial liver model using
hiPSCs and a rat decellularized liver scaffold. This hybrid liver
model with human liver function could open the door to develop
entirely non-antigenic transplantable artificial livers utilizing
autologous hiPSCs derived from the patients themselves.
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